1 2	A reporter virus particle seroneutralization assay for tick-borne encephalitis virus overcomes ELISA limitations
3	Rahel Ackermann-Gäumann <sup>1,2</sup> , Alexis Dentand <sup>3</sup> , Reto Lienhard <sup>1,2</sup> , Mohsan Saeed <sup>4,5</sup> , Margaret R. MacDonald <sup>6</sup> , Alix T Coste <sup>1,3</sup> , Valeria Cagno <sup>1,3*</sup>
5	
6	<sup>1</sup> Swiss National Reference Centre for Tick-Transmitted Diseases, Switzerland
7	<sup>2</sup> ADMED Microbiologie, La Chaux-de-Fonds 2300, Switzerland
8	<sup>3</sup> Lausanne University Hospital, University of Lausanne, Switzerland
9 10	<sup>4</sup> Department of Biochemistry & Cell Biology, Boston University Chobanian and Avedisian School of Medicine, Boston University, MA 02118
11	<sup>5</sup> National Emerging Infectious Diseases Laboratories, Boston University, MA 02118
12 13	<sup>6</sup> Laboratory of Virology and Infectious Disease, The Rockefeller University, New York NY 10065
14	
15	
16	
17	
18	* To whom correspondence should be addressed.
19	Valeria Cagno
20	Institute of Microbiology of Lausanne
21	Rue du Bugnon 48
22	1011 Lausanne
23	+41213142611
24	valeria.cagno@chuv.ch
25	

# 26 ABSTRACT

**Background** Tick-borne encephalitis (TBE) virus is the most common tick-transmitted Orthoflavivirus in Europe. Due to its non-specific symptoms, TBE is primarily diagnosed by ELISA-based detection of specific antibodies in the patient serum. However, cross-reactivity between orthoflaviviruses complicates the diagnosis. Specificity problems may be overcome by serum neutralization assays (SNT), however clinically relevant orthoflaviviruses require handling in biosafety level 3 (BSL-3) and they have highly divergent viral kinetics and cell tropisms.

Methods We present a reporter viral particle (RVP) based SNT in which the infectivity is measured by luminescence and that can be performed under BSL-2 conditions.

36 Findings The RVP-based SNT for TBEV exhibited a remarkable correlation with the 37 traditional virus-based SNT (R2=0.8614, p<0.0001). Notably, the RVP-based assay 38 demonstrated a sensitivity of 91.7% (95% CI: 87.2-97.1%) and specificity of 100% (95% CI: 39 79.6-100%). We also tested the cross-reactivity of serum samples in RVP-based assays 40 against other orthoflaviviruses (yellow fever virus, dengue virus type 2, Zika virus, West Nile 41 virus and Japanese encephalitis virus). Interestingly, in 90% of cases where a serum sample 42 had tested TBEV-positive by ELISA but negative by RVP-based SNT, we identified 43 antibodies against other orthoflaviviruses.

44 Interpretations The RVP-based seroneutralization assay show clinical relevance and broad-45 applicability.

46 **Funding** This study was supported by Bavarian Nordic grant to R.A. and V.C.

- 47
- 48
- 49

50 Keywords: seroneutralization, TBEV, reporter viral particle, serology

## 51 **RESEARCH IN CONTEXT**

#### 52 Evidence before this study

53 ELISA tests for orthoflavivirus serology are the method of choice in all diagnostic 54 laboratories despite the cross-reactivity issues. Although seroneutralization testing (SNT) provides more reliable results, it requires BSL-3 conditions and approximately a week to 55 56 obtain the results. However, developing tests with a broader applicability could overcome the 57 problem of cross-reactivity of antibodies against flaviviruses could be overcome leading to a 58 more accurate diagnosis and fewer non-useful results. Although alternative serological tests for other orthoflaviviruses have been investigated they have limitations, including lack of 59 60 uniformity for different orthoflaviviruses, the need for a BSL-3 laboratory to perform them, and results taking 4-5 days. The reporter viral particle system (RVP) we used in this study has 61 62 been reported for all orthoflaviviruses, except for YFV. However, its applicability has not 63 been tested in comparison to traditional methods with clinical samples.

### 64 Added value of this study

We tested the RVP system uniformly for different orthoflaviviruses and evaluated the sensitivity and specificity of SNT based on RVP compared to virus-based and to ELISA. Additionally, we found that false positives in ELISA in our clinical samples are frequently related to YFV positive samples.

## 69 Implications of all the available evidence

This study demonstrates the reliability and broad applicability of implementing RVP-based SNT in a clinical setting. This test can overcome the issues of false positive results from ELISA tests. Additionally, our data suggest that it is important to consider YFV exposure or vaccination anamnesis in patient's medical history. This is consistent with the phylogenetic similarity between YFV and TBEV if compared to other flaviviruses.

75

## 76 INTRODUCTION

77 Tick-borne encephalitis (TBE) caused by the tick-borne encephalitis virus (TBEV; 78 Orthoflavivirus encephalitidis, genus Orthoflavivirus, family Flaviviridae), is a major public 79 health problem in large parts of Europe and Asia. In Europe, TBE is endemic in at least 27 80 countries. TBE is typically caused by an infection involving one of three TBEV subtypes, 81 namely the European, Siberian, and Far Eastern subtypes. In addition, two other subtypes, i.e. 82 the Baikalian and the Himalayan subtype have been described more recently (1). TBEV is 83 primarily transmitted to humans by the bite of an infected Ixodid tick, although transmission 84 via the consumption of unpasteurized milk products from infected goats, sheep, or cows, is also possible (2). 85

86 Despite the availability of effective vaccines, disease incidence has significantly increased 87 during the past years (1). TBE may manifest as a disease of variable severity, ranging from 88 subclinical infections to severe courses with neurological involvement and potentially fatal 89 outcomes. Symptomatic disease is typically biphasic when caused by European subtype 90 viruses, including a viremic stage with flu-like symptoms starting about 8 days (range 4–28 91 days) after the tick bite, an asymptomatic interval of about one week (range 1–33 days), and a 92 second stage with neurological manifestations ranging from mild meningitis to severe 93 encephalitis with or without myelitis and spinal paralysis (1, 3, 4).

TBEV virions are spherical and contain a nucleocapsid surrounded by a lipid bilayer. The nucleocapsid consists of single-stranded positive-sense genomic RNA and the capsid protein (C). The surface of the lipid membrane incorporates an envelope (E) and a membrane (M) glycoprotein (5). In addition to the three structural proteins (C, E, and precursor M [prM]), the viral genome encodes for seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5).

100 Since clinical symptoms of TBE are often unspecific and similar to other central nervous 101 system diseases, the diagnosis of TBE has to be established in the laboratory. The methods of 102 choice for the diagnosis of TBE are serological assays (6). However, interpretation of 103 serologic test results is hampered by the high cross reactivity of the antigenic structure among orthoflaviviruses, especially in areas where other orthoflaviviruses co-circulate or where 104 105 vaccination against other orthoflaviviruses is regularly used (3). Examples of other medically 106 relevant orthoflaviviruses include yellow fever virus (YFV; Orthoflavivirus flavi), dengue virus (DENV; Orthoflavivirus denguei), Zika virus (ZIKV; Orthoflavivirus zikaense), West 107

Nile virus (WNV; Orthoflavivirus nilense), and Japanese encephalitis virus (JEV;
Orthoflavivirus japonicum). In Europe, WNV is endemic (7), whereas YFV, JEV, DENV, and
ZIKV infections are mainly described in association with travels to endemic areas (7-10).
However locally acquired cases of DENV have been described in recent years in different
European countries, including France in 2022 (11) and in Italy in 2023 (12). Vaccines against
JEV and YFV are administered prior to travelling to endemic areas, and simultaneous
administration of multiple vaccines is not uncommon (13, 14).

The antibody response to TBE is primarily targeted against the E and NS1 proteins of TBEV; most neutralizing antibodies recognize the viral E protein (1, 15). In order to differentiate neutralizing antibodies from cross-reactive non-neutralizing antibodies, plaque reduction neutralization, or microneutralization tests are typically used for medically relevant orthoflaviviruses, including TBEV. However, these tests are labor-intensive, time consuming, and involve the handling of infectious virus.

121 Reporter virus particles (RVPs) have been used in neutralization assays to measure antibodies 122 against several orthoflaviviruses including DENV, YFV, JEV, and WNV (16-25). In 123 particular, a system using RVPs encapsidating a sub-genomic replicon capable of expressing a 124 reporter gene following infection of target cells has been described. In this approach, 125 production of RVPs is accomplished by complementation of replicon RNA with 126 orthoflavivirus structural genes expressed in trans (26). Here, we present a comprehensive 127 assessment of the TBEV RVP seroneutralization test (SNT) using clinical samples in direct 128 comparison with ELISA and virus-based SNT. In addition, we simultaneously assessed the 129 neutralization capacity of sera against YFV, DENV-2, ZIKV, WNV, and JEV using RVP-130 based SNT assays. Our results underscore the shortcomings of traditional ELISA testing, 131 which sometimes yielded positive results for sera incapable of neutralizing TBEV. In contrast, 132 RVP-based SNT proved to be a robust alternative, comparable to virus-based SNT, and it can 133 be performed under BSL2 conditions. Notably, this method offers a significant advantage of 134 delivering results within 48h. Furthermore, cross-testing of serum samples against other 135 orthoflaviviruses provides a valuable means to directly discern the specificity of antibodies 136 within a given serum sample. These results argue for clinical implementation of RVP-based 137 seroneutralization testing of TBEV and other orthoflaviviruses.

#### 138 METHODS

#### 139 Cell lines

140 293T, 293F, A549, Vero, BHK21 and HUH 7 cells were obtained from the laboratory of 141 Sylvia Rothenberger (University of Lausanne, Lausanne) and Caroline Tapparel (University 142 of Geneva, Geneva) and cryopreserved at -196°C in liquid nitrogen. Individual aliquots were thawed and serially passaged for a maximum of 15 passages. All cell lines were maintained in 143 DMEM (1X) + GlutaMAX<sup>TM</sup> + 4.5 g/L D-Glucose + 110 mg/L Sodium Pyruvate (Gibco, 144 145 ThermoFisher Scientific) supplemented with 10% of fetal bovine serum (FBS, Pan Biotech) and penicillin/streptomycin 100 UI/ml (Gibco, ThermoFisher Scientific), in 75 m<sup>2</sup> culture 146 flasks (Sigma Aldrich) at 37°C in an incubator with 5% CO<sub>2</sub>. Cell suspensions were prepared 147 by removing the cell culture medium from confluent flasks and detaching the cells with 148 149 0.05% Trypsin EDTA (Gibco, ThermoFisher Scientific). Cells were counted using trypan 150 blue staining (Sigma Aldrich) and a Neubauer counting chamber.

151

#### 152 Viruses

TBEV strain Neudoerfl, strain Hypr, and YFV 17D, were kindly provided by Olivier Engler, 153 Spiez Laboratory, Switzerland. TBEV was grown on A549 cells, YFV on Vero cells. Viruses 154 155 were tittered by plaque assay on the cell line used for viral production, by infecting cells 156 preplated in 24 well plates at a density of 90,000 cells/well, with serial dilutions of viruses for 157 1h at 37°C, followed by removal of the inoculum and addition of 500  $\mu$ l of DMEM supplemented with methylcellulose 0.5%. The cells were fixed with formaldehyde 4% (Sigma 158 Aldrich) at 72hpi and stained with crystal violet (Sigma Aldrich). Viral stocks were stored at -159 80°C. 160

161

## 162 Plasmids

The plasmids containing the CprME sequence of TBEV Neudoerfl (27), ZIKV H/PF/2013
(28), DENV-2 (29) were kindly provided by the Rockefeller University. The DENV2, WNV
CprME and the pWNVII-Rep-Ren-IB replicon encoding the Renilla luciferase gene were
generously given by Theodore C. Pierson from the National Institute of Health (NIH, USA)
(26). The CprME plasmid of JEV (17) was kindly provided by Steve Whitehead, NIH, USA.
Plasmids were propagated using MAX Efficiency<sup>TM</sup> Stbl2<sup>TM</sup> Competent Cells (ThermoFisher

169 Scientific) according to manufacturer instructions. Extraction and purification of plasmids

170 from transformed bacteria was performed using the PureLink<sup>TM</sup> HiPure Plasmid Midiprep Kit

171 (ThermoFisher Scientific) and following manufacturer's instructions.

172 The YFV (strain Asibi) CprME expression construct was generated as follows: The CMV promoter region from pZIKV/HPF/CprME (plasmid described in (30), and obtained from Ted 173 174 Pierson, NIH) was amplified by PCR using primers RU-O-24611 and RU-O-24677. The region encoding Asibi CprME was amplified from the plasmid pACNR-2015FLYF-Asibi 175 176 (PMC7426275, and GenBank MT093734) using oligos RU-O-24676 and RU-O-24678. After gel purification of the PCR products, they were joined by assembly PCR and amplified using 177 178 oligos RU-O-24611 and RU-O-24678. The resultant PCR product was gel purified, digested 179 with SnaBI and SacII, and ligated overnight at 16°C using Toyobo Ligation High V2 ligase 180 into similarly digested and alkaline phosphatase treated pZIKV/HPF/CprME to generate 181 pYFV/Asibi/CprME. The ligation reaction was transformed into MC1061 E. coli cells, and 182 colonies selected on LB/carbenicillin plates for 20 h at 30°C. The sequence of the construct 183 was verified by Sanger sequencing using oligos RU-O-19736, RU-O-18162, RU-O-23860, 184 RU-O-24105, and RU-O-22695.

Oligo	Sequence (5' – 3')
RU-O-24611	CTTGACCGACAATTGCATGAAG
RU-O-24677	CTGAGCTTTACGACCAGACATAGCCTGCTTTTTTGTACAAAC
RU-O-24676	GTTTGTACAAAAAGCAGGCTATGTCTGGTCGTAAAGCTCAG
RU-O-24678	TTCGAACCGCGGCTGGGTCCTATTACGCCCCAACTCCTAGAGACAAAAAC
RU-O-19736	CCTATTGACGTCAATGACGG
RU-O-18162	GACGTTGGCTGCGAGCCCTG
RU-O-23860	TTGGCTGTTCTAAGGAAAGTTAAGA
RU-O-24105	CTGACCATTGCCTACCTT
RU-O-22695	AAATAGCCCCTGAAAGGCAGA

### **Table 1. Oligos for YFV CprME cloning.**

186

## 187 **RVP production and titration**

188 Co-transfection of the sub-genomic replicon WNVII-Rep-Ren-IB with a plasmid encoding 189 orthoflavivirus structural genes allows its replication, expression of luciferase, and packaging 190 by the structural proteins provided in trans to generate RVPs. These RVPs, expressing the 191 structural proteins of a specific orthoflavivirus (TBEV, ZIKV, DENV, WNV, JEV), can be 192 used for a single round of infection. RVPs were produced in 293T cells, seeded the day before 193 the transfection at 1x10<sup>6</sup> cells/well in poly-D-lysine-coated (ThermoFisher Scientific) 6-well

plates. Three  $\mu$ g of CprME plasmid and 1 $\mu$ g of the sub-genomic replicon pWNVII-Rep-Ren-IB were co-transfected using lipofectamine 3000 (ThermoFisher Scientific) following manufacturer's protocol. Lipid-DNA complexes were removed after 4h incubation at 37°C and replaced with cell culture medium. The culture medium containing RVPs was collected after 72-120 hours of incubation at 30°C, filtered through 0.2 µm filters (Sigma, Aldrich), and stored at -80°C in single-use aliquots.

Titration of RVPs was done by infecting HuH-7 cells plated in 96 well plates at a density of 1x10^4 cells/well with serial dilutions of RVPs at 37°C and assessing the luminescence 48 hours post infection (hpi). Luminescence was revealed with the Renilla-Glo® Luciferase Assay System (Promega) following manufacturer's protocol. The luciferase signal was assessed with a luminometer (TriStar LB 941 by Berthold Technologies and the MikroWin 2000 software).

206

#### 207 Serum samples

208 Fifty-three clinical serum samples were provided by the University Hospital of Lausanne, 209 Switzerland. They had been sent to the diagnostic labs for routine testing for TBEV IgG and 210 IgM antibodies. The sera were heat-inactivated at 56°C for 30 min and were stored at -80°C. 211 Additional sera (n=41) negative or positive for IgG and/or IgM antibodies for different 212 orthoflaviviruses were obtained from the diagnostic laboratory ADMED Microbiologie, 213 Switzerland, the University Hospital of Geneva, Switzerland, a ring trial organization 214 (INSTAND, Germany) and Seracare (LGC clinical diagnostic). These serum samples were 215 used for an initial evaluation of the RVP SNT assay.

216

## 217 TBEV IgG and IgM ELISA

TBEV-specific IgG and IgM antibodies were quantified using the VIROTECH TBE IgG/IgM ELISA kit (Virotech Diagnostic's GmbH, Germany) according to the manufacturer's instructions. OD measurements at 450/620 nm were done using the Biotek 800/TS plate reader, the calculations of the Virotech Units (VU) were then done manually according to the manufacturer's instructions. The cutoff for borderline results was fixed at >9 VU and the cutoff for positive results at >11 VU.

224

### 225 Selection of suitable cell lines

226 With the goal of identifying a common cell line for both RVP- and virus-based TBEV SNT, 227 several cell lines were tested for their ability to support infection by RVP and infectious virus. 228 The RVP infection was assessed by infecting cells with equal amounts of RVPs and 229 evaluating the luciferase expression at 48 hpi. The authentic virus infection was assessed by 230 monitoring the cytopathic effect of TBEV using cell viability assays. For this, 293T and HuH-7 cells were either mock-infected or infected with the wild type (WT) virus. 293T cells were 231 232 seeded at  $2x10^4$  cells/well while HuH-7 cells at  $1x10^4$  cells/well in 96 well plates. Cells 233 were infected with 100 plaque-forming units (PFU) of TBEV Hypr or Neudoerfl. At 72 hpi, 234 96 hpi and 120 hpi, the culture medium was discarded, and the cells were washed with 235 DMEM (1X) without serum. Then, 50 µL of MTT (Sigma Aldrich) diluted at 1:10 in DMEM 236 (1X) without serum was applied in each well. Cells were incubated at  $37^{\circ}$ C for 2h. The 237 supernatant was then discarded and replaced with 100 µL of dimethyl sulfoxide (DMSO; 238 Sigma Aldrich) per well to lyse the cells. Absorbance of cells was measured at 570 nm with a 239 spectrophotometer.

240

## 241 **RVP serum neutralization test**

242 In order to facilitate simultaneous evaluation of serum samples for their neutralizing capacity 243 against various orthoflaviviruses, we established an RVP SNT protocol that can be applied 244 uniformly to all RVPs used in this study (TBEV, YFV, ZIKV, DENV, WNV, JEV). The day 245 before the assay, HuH-7 cells were seeded in a 96-well plate at a density of  $1x10^4$  cells/well. 246 The RVPs were diluted in DMEM supplemented with 2.5% FBS to a concentration of  $1x10^{4}$ 247 RLU/well. 60  $\mu$ L of RVPs and 60  $\mu$ L of serum samples serially diluted 4-fold in DMEM 248 supplemented with 2.5% FBS were mixed in a 96 well V bottom plate and incubated for 1h at 249 37°C. Thereafter, the medium was removed from the cells in the 96-well plates, and the RVP 250 / serum sample mixture was added to the cells. A line of untreated control (containing RVP 251 and medium) and a line of uninfected control (containing only cell medium) were included in 252 every plate. This plate was then incubated for 48h at 37°C. To determine the results of 253 neutralization assays, 70 µL of supernatant was discarded from each well and replaced with 254 50 µL of Renilla-Glo® Luciferase Assay System (Promega). The luciferase signal was 255 assessed with a luminometer (TriStar LB 941 by Berthold Technologies and the MikroWin 256 2000 software). The concentration at which 99% of cell infection by the RPVs was inhibited

 $(IC_{99})$  was determined with nonlinear regression with GraphPad by calculating the percentages of infection at different dilutions compared to the infected untreated (i.e., no serum sample added) control.

260

## 261 Wild type virus serum neutralization test

262 As a reference method for TBEV, we used a standard WT virus serum neutralization test 263 (virus-based SNT) to determine the neutralizing activity of serum samples. Similarly, results 264 obtained using the YFV RVP SNT were compared to those obtained using a YFV WT SNT. 265 All work with infectious viruses was performed in a BSL-3 laboratory. 96-well plates were 266 seeded with  $1x10^{4}$  HuH-7 cells/well the day before infection. 60 µl of serum samples 267 serially diluted 4-fold were mixed with 60 µL of WT virus suspension, corresponding to 100 268 PFU/well. After an incubation period of 1h at 37°C, the serum sample / virus mixture was 269 added to the cells in the 96-well plates, from which the medium had been removed. As for the 270 RVP neutralization assay, a line of untreated control (containing WT virus and medium) and a 271 line of uninfected control (containing only cell medium) were included in every plate. The plate was incubated at 37° for 4 (TBEV Hypr, YFV) to 5 days (TBEV Neudoerfl). Cytopathic 272 273 effect was assessed by coloration of cells with crystal violet and optical microscopy. The IC99 274 was determined based on the last dilution in which the sera showed complete protection from 275 cytopathic effect. The cutoff for a positive WT SNT result was set at >1:8.

276

## 277 RVP SNT assay characteristics and cutoff definition

The sensitivity and specificity of the TBEV RVP SNT were defined based on receiver operating curve (ROC) analysis, for which we used the TBEV WT SNT results as a reference standard. The cutoff for qualitative test evaluation (positive/negative) was defined based on the maximal Youden's index (31). This cutoff value was implemented consistently across all RVP SNTs.

283

#### 284 Correlation analysis

We utilized a linear regression model to assess the correlation between the quantitative RVP SNT and WT SNT results, as well as between the RVP SNT and the ELISA as well as the

287	WT SNT and the ELISA results. Graphs were constructed by reporting the log of the 1/IC99
288	of each serum for the RVP SNT, the WT SNT, or the IgG or IgM ELISA. All analyses were
289	performed using GraphPad Prism 9, a p value $< 0.05$ was considered as significant.
290	
291	Ethics approval
292	Ethical authorization to re-use samples collected by the serology of CHUV has been granted
293	by CER-VD, project n°2023-01971.
294	
295	Data sharing
296	Raw data of SNT are available upon reasonable requests to valeria.cagno@chuv.ch
297	
298	Role of the funding source
299	The project was financed by a research grant from Bavarian Nordic, but the authors were
300	completely independent from the funding source regarding the study plan, analysis, writing

and submission. The salary of V.C is supported by the Swiss National Science
Foundation [PZ00P3\_193,289]

#### RESULTS 303

#### 304 **Optimization of SNT conditions**

305 With the goal to identify a common cell line for both RVP-based and virus-based SNT for 306 TBEV, three cell lines were tested for their ability to express the reporter gene following RVP 307 infection (Supplementary Figure 1A) and their potential to show a cytopathic effect upon WT virus infection (Supplementary Figure 1B-C). TBEV stocks were produced in A549 cells. 308 309 However, these cells yielded poor luminescence signal following RVP infection compared to 310 other cell lines, indicating limited expression of replicon in these cells (Supplementary Figure 1A). Among the permissive cell lines, HuH-7 showed the best profile in both assays and was 311 312 therefore used in all subsequent experiments. These cells were also susceptible to RVPs derived from WNV, JEV, YFV, DENV, and ZIKV (Supplementary Figure 1D). 313

314 Next, we evaluated the performance of RVP-based SNT assays using three to seven serum 315

samples for each of the TBEV, WNV, JEV, YFV, DENV, and ZIKV and two samples

negative for antibodies against the respective orthoflaviviruses included in this study (TBEV, 316

317 WNV, JEV, YFV, DENV, and ZIKV). For all positive samples, we were able to calculate the

IC<sub>99</sub> values using the respective RVP SNT assay, whereas none of the negative samples 318

319 exhibited neutralizing activity against their respective RVPs (Supplementary Figure 2).

320

#### 321 **RVP SNT assay characteristics and cutoff definition**

322 The cutoff for qualitative test evaluation (negative/positive) of the TBEV RVP-based SNT 323 was defined by ROC analysis using TBEV virus-based SNT results as a reference. Youden's 324 index was maximal at a value of 1:40, with a test sensitivity of 91.7% (95% CI: 87.2-97.1%) 325 and a test specificity of 100% (95% CI: 79.6-100%) (Supplementary Figure 3). The cutoff 326 value of  $\geq$ 1:40, defined using this approach, was implemented consistently across all RVP 327 SNTs.

328

#### **RVP-based SNT and virus-based SNT results for TBEV** 329

330 A total of 53 serum samples for which TBEV-specific IgG and IgM titers had been assessed 331 by ELISA-based routine testing (Virotech TBE IgG/IgM ELISA kit) were analyzed using

332 RVP-based and virus-based (strain Neudoerfl) SNT assays. The results are shown in Table 2.

333 94.3% of samples (50/53) yielded concordant results with both RVP-based and virus-based 334 SNT assays; the remaining 3 samples with discordant results are probably false-negative in 335 the RVP-based SNT as compared to TBEV WT SNT. The results of the RVP-based assay 336 differed from those of ELISA for 12 samples (22.6%). Of these, two samples were positive by RVP-based assay but negative or borderline by ELISA; both samples were confirmed positive 337 by the virus-based SNT assay. Ten samples tested negative in RVP-based assay but positive 338 in TBEV IgG ELISA (7 negative, 1 borderline, and 2 positive for IgM), whereof 8 were 339 340 confirmed negative by virus-based SNT.

	ELISA <sup>1</sup>				RVP	SNT <sup>2</sup>	WT	SNT <sup>3</sup>	discording qualitative results <sup>4</sup>			
sample	IgG qn	IgG ql	IgM qn	IgM ql	Ig tot. qn	Ig tot. ql	Ig tot. qn	Ig tot. ql	RVP SNT / WT SNT	RVP SNT / ELISA	WT SNT / ELISA	
CH01	<9	n	<9	n	<1:8	n	<1:8	n				
CH02	<9	n	<9	n	<1:8	n	<1:8	n				
CH03	<9	n	<9	n	<1:8	n	<1:8	n				
CH04	<9	n	<9	n	<1:8	n	<1:8	n				
CH05	<9	n	<9	n	<1:8	n	<1:8	n				
CH06	<9	n	<9	n	<1:8	n	<1:8	n				
CH07	<9	n	<9	n	<1:8	n	<1:8	n				
CH08	<9	n	<9	n	<1:8	n	<1:8	n				
CH09	<9	n	<9	n	1:10	n	1:32	р	x		х	
CH10	<9	n	<9	n	1:96	р	1:32	р		x	х	
CH11	<9	n	<9	n	1:45	р	1:32	р		x	х	
CH12	<9	n	14	р	1:49	р	1:128	р				
CH13	10	?	<9	n	1:39	n	1:8	n				
CH14	17	р	<9	n	<1:8	n	<1:8	n		х	х	
CH15	21	р	<9	n	1:12	n	1:8	n		x	х	
CH16	32	р	<9	n	<1:8	n	1:8	n		х	х	
CH17	35	р	<9	n	<1:8	n	<1:8	n		х	х	
CH18	24	р	<9	n	1:17	n	1:8	n		x	х	
CH19	51	р	<9	n	<1:8	n	1:8	n		х	х	
CH20	40	р	<9	n	<1:8	n	<1:8	n		х	х	
CH21	24	р	< 9	n	1:398	р	1:80	р				
CH22	32	р	< 9	n	1:57	р	1:128	р				
CH23	60	р	< 9	n	1:336	р	1:104	р				
CH24	34	р	<9	n	1:105	р	1:32	р				
CH25	60	р	<9	n	1:559	р	1:320	р				
CH26	45	р	<9	n	1:588	р	1:2720	р				
CH27	26	р	<9	n	1:533	р	1:200	р				
CH28	38	р	<9	n	1:55	р	1:80	р				

CH29	37	р	<9	n	1:64	р	1:320	р			
CH30	44	p	<9	n	1:83	p	1:32	p			
CH31	23	р	<9	n	1:125	р	1:32	р			
CH32	12	р	<9	n	1:85	р	1:32	р			
CH33	12	р	<9	n	1:54	р	1:32	р			
CH34	19	р	<9	n	1:336	р	1:128	р			
CH35	29	р	<9	n	1:47	р	1:128	р			
CH36	41	р	<9	n	1:74	р	1:128	р			
CH37	25	р	10	?	<1:8	n	1:80	р	х	х	
CH38	54	р	10	?	1:3145	р	1:3200	р			
CH39	14	р	14	р	1:16	n	1:8	n		х	х
CH40	41	р	21	р	1:8	n	1:32	р	x	х	
CH41	32	р	62	р	1:8183	р	1:3200	р			
CH42	17	р	13	р	1:215	р	1:200	р			
CH43	38	р	100	р	1:3921	р	1:2600	р			
CH44	17	р	45	р	1:1971	р	1:1280	р			
CH45	24	р	51	р	1:1641	р	1:2048	р			
CH46	34	р	21	р	1:40	р	1:512	р			
CH47	49	р	22	р	1:364	р	1:512	р			
CH48	30	р	65	р	1:2002	р	1:3584	р			
CH49	36	р	67	р	1:1579	р	1:512	р			
CH50	34	р	45	р	1:833	р	1:896	р			
CH51	47	р	50	р	1:143	р	1:896	р			
CH52	15	р	50	р	1:7032	р	1:12800	р			
CH53	38	р	31	р	1:291	р	1:128	р			

341


342 **Table 2.** Anti-TBEV antibody test results of clinical samples. <sup>1</sup> Virotech TBE IgG/IgM ELISA; 343 results are given in Virotech Units / ml; cutoffs for negative and positive results were set at  $\leq 9$  and  $\geq$ 11 VU/ml, respectively. Values not divisible by 4 are obtained by the mean of two independent SNT; <sup>2</sup> 344 TBEV reporter virus particle seroneutralization test; results are given as IC99; the cutoff for a 345 346 positive result was set at  $\geq 1:40$ ; <sup>3</sup> TBEV wild type seroneutralization test; results are given as IC99; the cutoff for a positive result was set at >1:8;  $^{4}$  discordance of qualitative results between different 347 348 tests are indicated with x. For this comparison, ELISA was regarded as positive if either IgG or IgM 349 or both tested positive; borderline ELISA results were regarded as negative.

350

Linear regression analysis was used to assess the agreement between quantitative test results obtained from RVP-based versus virus-based (strain Neudoerfl) SNT, as well as between SNTs and ELISA (Figure 1). All correlations were significant (p<0.001, T test for linear regression). A high correlation coefficient ( $R^2$  0.86) was obtained for RVP-based SNT versus

virus-based SNT (Figure 1A), RVP-based SNT versus IgM ELISA (R<sup>2</sup> 0.89), and virus-based





357

Figure 1. Linear regression analysis comparing results obtained using the TBEV RVP SNT, the
TBEV WT SNT, and TBEV IgG and IgM ELISA. SNT results are expressed as log 1/1C99, ELISA
results as log VU/ml. A) correlation between the TBEV RVP SNT and the TBEV WT SNT (strain
Neudoerfl). B) correlation between the TBEV RVP SNT and TBEV IgG ELISA results. C) correlation
between the TBEV WT SNT and TBEV IgG ELISA results. D) correlation between the TBEV RVP SNT
and TBEV IgM ELISA results. E) correlation between TBEV WT SNT and TBEV IgM ELISA results.
Linear regression was calculated with GraphPad Prism, correlation coefficient and p values (T test

for linear regression) are indicated in each panel. Dotted lines represent the cutoff of the respective
tests.

367

# 368 Impact of virus strain on virus-based SNT results

For a subset of samples, we evaluated the concordance between RVP-based and virus-based SNT results when using a different virus strain, Hypr, in the virus-based SNT. Qualitatively, the virus based SNT results were identical in 17 out of 18 samples (94.4%) when using the strains Neudoerfl and Hypr, while quantitative results showed some variation (Supplementary Table 1). The linear regression comparing RVP (strain Neudoerfl) and virus-based (strain Hypr) SNT results R<sup>2</sup> of 0.55, as compared to the R<sup>2</sup> value of 0.86 when comparing RVPbased and virus-based (strain Neudoerfl) SNT, respectively (Supplementary Figure 4).

376

### 377 Evaluation of selected sera for crossreactivity

378 The results of the RVP-based assay differed from those of ELISA for 12 samples (22.6%). 379 These samples, one borderline in ELISA and negative in the RVP-based assay, and 7 380 additional, randomly selected samples were tested for their neutralizing potential against 381 RVPs of 5 different orthoflaviviruses (ZIKV, YFV, DENV, WNV, JEV). The results are 382 shown in Table 3. Nine of the 10 serum samples (90%) that were TBEV-positive by ELISA 383 but negative by RVP-based SNT tested positive for neutralizing antibodies against other 384 orthoflaviviruses. Moreover, we found that seven of the 15 ELISA-positive samples (46.7%) 385 contained neutralizing antibodies against multiple orthoflaviviruses.

Clinical informatio		JE RVP	NV SNT <sup>2</sup>		ENV SNT <sup>2</sup>			YF RVP S		ZIF RVP S		TB RVP		SA <sup>1</sup>	ELI		
	Ig tot. ql	Ig tot. qn	Ig tot. ql	Ig tot. qn	Ig tot. ql	Ig tot. qn	Ig tot. ql	Ig tot. qn	Ig tot. ql	Ig tot. qn	Ig tot. ql	Ig tot. qn	IgM ql	IgM qn	IgG ql	IgG qn	sample
Diagnosed TBE cas	n	< 1:8	n	< 1:8	n	< 1:8	n	1:13	n	< 1:8	р	1:8183	р	62	р	32	CH41
Diagnosed TBE cas	n	< 1:8	n	< 1:8	р	1:47	р	1:134	n	< 1:8	р	1:3921	р	100	р	38	CH43
Vaccinated against TBEV, JEV, YFV	р	1:77	р	1:48	n	< 1:8	р	1:659	n	< 1:8	р	1:398	n	< 9	р	24	CH21
Vaccinated against TBEV, JEV, YFV	р	1:649	n	1:20	n	< 1:8	р	1:185	n	< 1:8	р	1:57	n	< 9	р	32	CH22
Vaccinated against TBEV, YFV	n	< 1:8	n	< 1:8	n	< 1:8	р	1:1132	n	< 1:8	р	1:336	n	< 9	р	60	CH23
Travel in Mexico, South Thailand, Peru Neurological sympton No data Origin Vietnam	n	< 1:8	n	1:36	n	< 1:8	р	1:90	n	< 1:8	n	1:16	р	14	р	14	CH39
Neurological sympto	n	1:29	р	1:145	n	< 1:8	р	1:112	n	< 1:8	n	< 1:8	?	10	р	25	CH37
No data	n	< 1:8	n	< 1:8	n	1:12	р	1:1557	n	< 1:8	n	1:8	р	21	р	41	CH40
Origin Vietnam		n.a.		n.a.		n.a.	р	1:426	n	< 1:8	n	< 1:8	n	<9	р	17	CH14
Travel in Brazil, Thail. Mexico Meningo-encephalitis unknown etiology Neurological sympto	n	< 1:8	n	< 1:8	n	< 1:8	р	1:1786	n	< 1:8	n	1:12	n	<9	р	21	CH15
Meningo-encephalitis unknown etiology	n	< 1:8	n	< 1:8	n	1:17	р	1:87	n	< 1:8	n	< 1:8	n	<9	р	32	CH16
associated to glioblasto	n	< 1:8	р	1:40	n	< 1:8	n	< 1:8	n	< 1:8	n	1:17	n	<9	р	24	CH18
Origin Indonesia Diagnosed WNV infec	n	1:20	n	< 1:8	р	1:102	р	1:54	n	< 1:8	n	< 1:8	n	<9	р	40	CH20
DENV and WNV. Tes	n	< 1:8	р	1:97	р	1:62	р	1:1588	n	< 1:8	n	< 1:8	n	<9	р	35	CH17
Meningo-Encephaliti unknown etiology	n	< 1:8	n	< 1:8	n	< 1:8	n	< 1:8	n	1:8	n	< 1:8	n	<9	р	51	CH19
positive for IgM for W Meningo-Encephaliti unknown etiology Vaccinated with two do TBEV vaccine No data	n	1:11	n	< 1:8	n	< 1:8	n	1:22	n	< 1:8	n	1:39	n	<9	?	10	CH13
No data	n	< 1:8	n	< 1:8	n	< 1:8	n	< 1:8	n	< 1:8	р	1:96	n	<9	n	<9	CH10

CH11	<9	n	<9	n	1:45	р	< 1:8	n	1:377	р	< 1:8	n	1:11	n	1:36	n	Vaccinated with one dose of TBEV - No vaccination for Y
CH06	<9	n	<9	n	< 1:8	n	< 1:8	n	< 1:8	n	< 1:8	n	< 1:8	n	< 1:8	n	No data
CH09	<9	n	<9	n	1:10	n	< 1:8	n	< 1:8	n	< 1:8	n	< 1:8	n	< 1:8	n	Vaccinated with two doses of TBEV vaccine – immunosuppressed patien
Table 2 D	VD CN	TT moon	Ite oge	inct m	ultiple of	nth of lovin	in land	Vinataal	TDE LC	I.AM EI	ICA . magne	Ita ana aina	17:	tool II.	ita / mile a	utoffa fo	n n a a atima 🗸 🗸

**Table 3. RVP SNT results against multiple orthoflaviviruses.**<sup>1</sup> Virotech TBE IgG/IgM ELISA; results are given in Virotech Units / ml; cutoffs for negative

387 and positive results were set at  $\leq 9$  and  $\geq 11$  VU/ml, respectively; <sup>2</sup> reporter virus particle seroneutralization test; results are given as IC99; the cutoff for a

388	positive	result	was	set	at	$\geq 1:40.$	n.a.	not	assessed
500	positive	105000	Wab	501	<i>cu</i>	_1.70.	11.01.	1101	<i>uppeppe</i>

Clinical information was available for 17/20 samples. Thereof, 12 were in accordance with
(samples CH41, CH22, CH23, CH15, CH20, CH17) or partially matched the SNT results
(samples CH43, CH21, CH37, CH39, CH15, CH20, CH11), whereas 5 did not provide
sufficient evidence to explain the results obtained (samples CH14, CH19, CH09, CH18,
CH16).

Twelve of the 15 samples (80%) that were positive by TBEV IgG ELISA showed a neutralizing activity against YFV. This percentage, although partly supported by the clinical data, is surprisingly high when compared to the assumed seroprevalence of YFV in the population. Nonetheless, the presence of YFV antibodies in these samples was confirmed by both RVP-based and virus-based SNT (Supplementary Table 2). with full qualitative concordance between the two methods.

## 401 **DISCUSSION**

402 Despite the availability of effective vaccines, TBEV continues to pose a considerable threat to 403 public health due to its expanding geographical distribution and the increasing number of 404 reported cases (1). Serological diagnosis plays a crucial role in the management and surveillance of TBEV infections. However, it is fraught with challenges, primarily stemming 405 406 from the cross-reactivity among orthoflaviviruses. This cross-reactivity can result in false-407 positive results and misdiagnosis, especially in regions where multiple orthoflaviviruses co-408 circulate, for persons having traveled to areas endemic for other orthoflaviviruses, or for 409 persons recently vaccinated against other orthoflaviviruses (3). While most laboratories use 410 ELISA for routine serological diagnosis, a reliable differentiation of virus-neutralizing from cross-reactive virus-binding but non-neutralizing antibodies is only possible using serum 411 412 neutralization tests. Here, we describe the evaluation of an RVP-based test system, allowing 413 for the simultaneous detection of antibodies directed against multiple orthoflaviviruses. The 414 RVP-based SNT can serve as a rapid (within 48 hours) substitute for the virus-based SNT, requiring only BSL-2 facilities and demonstrating a reliable performance. The concurrent 415 416 identification of antibodies against other orthoflaviviruses holds significant importance.

RVP-based SNTs for different orthoflaviviruses have been established using different cell lines, including BHK-J cells (24), BHK-21 cells (26), Vero cells (25), and HUH-7.5 cells (27). In our experiments, we found that HUH7 cells were well suited for the effective execution of TBEV, YFV, DENV, ZIKV, WNV, and JEV RVP SNTs. The readout of our assay using Renilla luciferase was performed 48hpi, which is in line with the readout of a test using Gaussia luciferase (32), while others described readout times of 3 to 5-6 days using NanoLuc or GFP, respectively(33, 34).

424 A major difficulty when establishing diagnostic tests is the definition of an appropriate cutoff, 425 which discriminates positive from negative results and requires a compromise between 426 sensitivity and specificity. We performed an ROC analysis and set the cutoff point for the 427 TBEV RVP-based SNT at the value resulting in the highest Youden's index, maximizing the summation of sensitivity and specificity (31). One of the possible limitations of our study is 428 429 that cutoff values were not defined for each orthoflavivirus RVP SNTs individually, but rather 430 by applying the cutoff defined for the TBEV RVP SNT to all other test systems While this offers the opportunity of harmonizing the readout of all tests, sensitivity and / or specificity of 431 432 RVP-based SNTs other than TBEV might not be optimal. Due to the small sample size, an

individual cutoff definition based on ROC analysis for each individual RVP SNT was notpossible in this study.

435 When compared to the virus-based SNT (strain Neudoerfl), the RVP-based SNT showed a 436 sensitivity of 91.7% and a specificity of 100% for TBEV. Assay specificity is of high 437 importance for a diagnostic assay that may be used as a confirmatory test. An assay sensitivity 438 of 91.7% is acceptable, though not optimal. On the other hand, we did also observe positive 439 results by RVP-based SNT for samples testing negative in ELISA (samples CH10, CH11, 440 Table 2), which were confirmed positive by the virus-based SNT. Thus, while ELISA tests for 441 the detection of anti-TBEV IgG antibodies generally show a high sensitivity, reaching up to 442 99% (35), it is important to acknowledge the potential for false-negative outcomes in these 443 assays. Given the quick availability of results with the RVP-based SNT, opting for this test 444 may offer advantages.

445 Discording results were obtained for 22.6% of samples (12/53) when comparing the RVP-446 based SNT to ELISA. Thereof, 10 were false-positive in ELISA. The pronounced cross-447 reactivity of antibodies against different orthoflaviviruses in ELISA test systems is well 448 known (3). In fact, we could demonstrate the presence of antibodies against other 449 orthoflaviviruses in 9/10 samples yielding false-positive results by ELISA (Table 3). 450 Neurological symptoms of TBE are similar to those of other viral infections of the brain, 451 including for instance WNV, which is endemic in Europe (7). Conducting a test that can both 452 rule out cross-reactivity and simultaneously evaluate specific seroneutralization for multiple 453 orthoflaviviruses is thus highly clinically significant. This capability is one of the significant 454 advantages provided by the here-described RVP-based SNTs.

Interestingly, the results of IgM ELISA showed a higher level of correlation with those from 455 RVP-based SNT (R<sup>2</sup> 0.89, Figure 1D) and virus-based SNT (R<sup>2</sup> 0.91, Figure 1E) compared to 456 those from IgG ELISA ( $\mathbb{R}^2 0.27$  and 0.37, respectively, Figure 1B and 1C). This discrepancy 457 458 likely arises from the fact that a substantial number of samples that test positive solely for IgG are from individuals who have been vaccinated against different (crossreactive) 459 460 orthoflaviviruses or have recovered from an earlier infection, whereas those that also test 461 positive for IgM are typically associated with clinical TBE cases. It is also in line with the 462 observation that tests for anti-TBEV IgM are usually more specific than IgG tests with regard 463 to cross-reactivity with other orthoflaviviruses (36, 37).

While there was a strong correlation between RVP-based and virus-based SNT assays when the strain Neudoerfl was used in both assays ( $R^2$  0.86, Figure 1A), TBEV RVP SNT results correlated less well to TBEV WT SNT results using the strain Hypr ( $R^2$  0.55, Supplementary Figure 4), as expected since the TBEV RVP utilized in this study is derived from the genetic sequence of the Neudoerfl strain of TBEV. The results are in line with literature, where it has been shown that antibodies generated upon vaccination with specific strains do not equally efficiently neutralize different wild type virus strains (38, 39).

471 Among the subset of samples tested for their neutralizing capacity against multiple 472 orthoflaviviruses, we found a high proportion of samples (8/20) positive for antibodies against 473 more than one virus (Table 3). Thus, multiple vaccinations or exposures were common in this set of samples, as verified in some cases by concordance between clinical information and 474 475 SNT results. However, for some sera the clinical information did not provide sufficient 476 evidence to explain the SNT results or only partially matched the SNT results, possibly linked 477 to an incomplete dataset or anamnesis may not have included questions about different 478 orthoflavivirus vaccinations. Our findings underscore the importance of simultaneous testing 479 against a large panel of orthoflaviviruses. Only by doing so can we unveil the complete range 480 of neutralizing antibodies present in a sample.

Remarkably, a significant number of samples yielded positive results for neutralizing 481 482 antibodies against YFV (Table 3). To address concerns about the specificity of the YFV RVP-483 based SNT, all results were verified using the virus-based SNT (Supplementary Table 2). The observed positivity rate is likely influenced by our choice to conduct RVP SNTs for multiple 484 485 orthoflaviviruses on selected samples. This selection primarily relied on discordant outcomes 486 between TBEV ELISA and TBEV RVP SNT results. Nevertheless, YFV vaccination is a non-487 negligible cause of false-positive TBEV (IgG) ELISA results, given the (travel) vaccination 488 recommendations. However, it is important to consider that YFV vaccination can significantly contribute to false-positive TBEV (IgG) ELISA results, especially in light of travel 489 vaccination guidelines (40) and the phylogenetic similarity of YFV to TBEV (12). 490

We found two samples positive in TBEV ELISA testing but negative in all orthoflavivirus RVP-based SNTs (TBEV, ZIKV, YFV, DENV, WNV, JEV). While this might be due to false-negative results in RVP-based SNTs, we must also keep in mind other less-well characterized orthoflaviviruses which might be of medical importance but have not been included in our study. These could be tick-borne (e.g., Powassan virus [*Orthoflavivirus powassense*], Omsk hemorrhagic fever virus [*Orthoflavivirus omskense*] or mosquito borne

497 pathogens (e.g., Usutuvirus [Orthoflavivirus usutuense], Wesselsbron virus [Orthoflavivirus
498 wesselsbronense]) (41, 42).

Taken together, our results emphasize the importance of performing neutralization instead of ELISA testing for diagnosing orthoflaviviral infections. While this has been labor-intensive and requiring high biosafety level standards, the RVP-based neutralization approach for multiple orthoflaviviruses we described provides a notable advantage, offering a more accessible and cost-effective platform and thus enhancing the diagnostic capabilities of healthcare institutions.

505

#### 506 **AKNOWLEDGEMENTS**

507 The authors would like to thank Emilie Ruegger and Alexandre Mamin for their support in 508 providing the sera, Adriana Renzoni for providing reference sera from the Swiss Center for 509 Emerging viruses and the members of the Swiss National Reference Center for Tick 510 Transmitted Diseases for fruitful discussions.

# 511 **REFERENCES**

Ruzek D, Avsic Zupanc T, Borde J, Chrdle A, Eyer L, Karganova G, et al. Tick-borne encephalitis
 in Europe and Russia: Review of pathogenesis, clinical features, therapy, and vaccines. Antiviral Res.
 2019;164:23-51.

Martello E, Gillingham EL, Phalkey R, Vardavas C, Nikitara K, Bakonyi T, et al. Systematic
 review on the non-vectorial transmission of Tick-borne encephalitis virus (TBEv). Ticks Tick Borne Dis.
 2022;13(6):102028.

Lindquist L. Tick-borne encephalitis. In: Tselis A, editor. Handbook of Clinical NEurology:
 Elsevier; 2014. p. 531-59.

520 4. Lindquist L, Vapalahti O. Tick-borne encephalitis. Lancet. 2008;371(9627):1861-71.

521 5. Fuzik T, Formanova P, Ruzek D, Yoshii K, Niedrig M, Plevka P. Structure of tick-borne

encephalitis virus and its neutralization by a monoclonal antibody. Nat Commun. 2018;9(1):436.

523 6. Holzmann H. Diagnosis of tick-borne encephalitis. Vaccine. 2003;21 Suppl 1:S36-40.

5247.Kaaijk P, Luytjes W. Are we prepared for emerging flaviviruses in Europe? Challenges for525vaccination. Hum Vaccin Immunother. 2018;14(2):337-44.

Overbosch FW, Schinkel J, Matser A, Koen G, Prange I, Prins M, et al. Dengue, chikungunya
 and Zika virus infections among Dutch travellers to Suriname: a prospective study during the
 introduction of chikungunya and Zika virus, 2014 to 2017. Euro Surveill. 2023;28(2).

529 9. Wiltz P. Identifying and Managing Vector-Borne Diseases in Migrants and Recent Travelers in 530 the Emergency Department. Curr Emerg Hosp Med Rep. 2023;11(2):58-65.

53110.Amicizia D, Zangrillo F, Lai PL, Iovine M, Panatto D. Overview of Japanese encephalitis disease532and its prevention. Focus on IC51 vaccine (IXIARO((R))). J Prev Med Hyg. 2018;59(1):E99-E107.

533 11. Cochet A, Calba C, Jourdain F, Grard G, Durand GA, Guinard A, et al. Autochthonous dengue 534 in mainland France, 2022: geographical extension and incidence increase. Euro Surveill. 2022;27(44).

535 12. Del Manso M DME, Perego G, Petrone D, Mateo-Urdiales A, Caporali MG, Bella A, Venturi G,

536 Di Luca M, Giannitelli S, Ferraro F, Pezzotti P, Riccardo F. Arbovirosi in Italia - 2023

537<a href="https://www.epicentro.iss.it/arbovirosi/dashboard2023">https://www.epicentro.iss.it/arbovirosi/dashboard2023</a> [updated 11.09.2023. Available from:538<a href="https://www.epicentro.iss.it/arbovirosi/dashboard2">https://www.epicentro.iss.it/arbovirosi/dashboard2023</a> [updated 11.09.2023. Available from:

Jaeger VK, Tschudi N, Ruegg R, Hatz C, Buhler S. The elderly, the young and the pregnant
 traveler -- A retrospective data analysis from a large Swiss Travel Center with a special focus on
 malaria prophylaxis and yellow fever vaccination. Travel Med Infect Dis. 2015;13(6):475-84.

Sandberg JT, Lofling M, Varnaite R, Emgard J, Al-Tawil N, Lindquist L, et al. Safety and
immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or
Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial. PLoS Negl
Trop Dis. 2023;17(2):e0010616.

546 15. Chambers TJ, Diamond MS. Pathogenesis of flavivirus encephalitis. Adv Virus Res. 547 2003;60:273-342.

54816.Gehrke R, Ecker M, Aberle SW, Allison SL, Heinz FX, Mandl CW. Incorporation of tick-borne549encephalitis virus replicons into virus-like particles by a packaging cell line. J Virol. 2003;77(16):8924-55033.

55117.Gromowski GD, Firestone CY, Hanson CT, Whitehead SS. Japanese encephalitis virus vaccine552candidates generated by chimerization with dengue virus type 4. Vaccine. 2014;32(25):3010-8.

553 18. Garg H, Mehmetoglu-Gurbuz T, Joshi A. Virus Like Particles (VLP) as multivalent vaccine
554 candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus. Sci Rep.
555 2020;10(1):4017.

55619.Jones CT, Patkar CG, Kuhn RJ. Construction and applications of yellow fever virus replicons.557Virology. 2005;331(2):247-59.

Pierson TC, Diamond MS, Ahmed AA, Valentine LE, Davis CW, Samuel MA, et al. An infectious
West Nile virus that expresses a GFP reporter gene. Virology. 2005;334(1):28-40.

560 21. Mattia K, Puffer BA, Williams KL, Gonzalez R, Murray M, Sluzas E, et al. Dengue reporter virus 561 particles for measuring neutralizing antibodies against each of the four dengue serotypes. PLoS One. 562 2011;6(11):e27252. 563 22. Garg H, Sedano M, Plata G, Punke EB, Joshi A. Development of Virus-Like-Particle Vaccine and 564 Reporter Assay for Zika Virus. J Virol. 2017;91(20). 565 Agudelo M, Palus M, Keeffe JR, Bianchini F, Svoboda P, Salát J, et al. Broad and potent 23. 566 neutralizing human antibodies to tick-borne flaviviruses protect mice from disease. J Exp Med. 567 2021;218(5). 568 24. Lücke AC, Vom Hemdt A, Wieseler J, Fischer C, Feldmann M, Rothenfusser S, et al. High-569 Throughput Platform for Detection of Neutralizing Antibodies Using Flavivirus Reporter Replicon 570 Particles. Viruses. 2022;14(2). 571 25. Bohning K, Sonnberg S, Chen HL, Zahralban-Steele M, Powell T, Hather G, et al. A high 572 throughput reporter virus particle microneutralization assay for quantitation of Zika virus neutralizing 573 antibodies in multiple species. PLoS One. 2021;16(4):e0250516. 574 Pierson TC, Sanchez MD, Puffer BA, Ahmed AA, Geiss BJ, Valentine LE, et al. A rapid and 26 575 quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. 576 Virology. 2006;346(1):53-65. 577 Agudelo M, Palus M, Keeffe JR, Bianchini F, Svoboda P, Salat J, et al. Broad and potent 27. 578 neutralizing human antibodies to tick-borne flaviviruses protect mice from disease. J Exp Med. 579 2021;218(5). 580 28. Dowd KA, DeMaso CR, Pelc RS, Speer SD, Smith ARY, Goo L, et al. Broadly Neutralizing Activity 581 of Zika Virus-Immune Sera Identifies a Single Viral Serotype. Cell Rep. 2016;16(6):1485-91. 582 Ansarah-Sobrinho C, Nelson S, Jost CA, Whitehead SS, Pierson TC. Temperature-dependent 29. 583 production of pseudoinfectious dengue reporter virus particles by complementation. Virology. 2008;381(1):67-74. 584 585 30. Robbiani DF, Bozzacco L, Keeffe JR, Khouri R, Olsen PC, Gazumyan A, et al. Recurrent Potent 586 Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. Cell. 2017;169(4):597-609 e11. 587 Habibzadeh F, Habibzadeh P, Yadollahie M. On determining the most appropriate test cut-off 31. 588 value: the case of tests with continuous results. Biochem Med (Zagreb). 2016;26(3):297-307. 589 32. Lucke AC, Vom Hemdt A, Wieseler J, Fischer C, Feldmann M, Rothenfusser S, et al. High-590 Throughput Platform for Detection of Neutralizing Antibodies Using Flavivirus Reporter Replicon 591 Particles. Viruses. 2022;14(2). 592 Li W, Ma L, Guo LP, Wang XL, Zhang JW, Bu ZG, et al. West Nile virus infectious replicon 33. 593 particles generated using a packaging-restricted cell line is a safe reporter system. Sci Rep. 594 2017;7(1):3286. 595 34. Matsuda M, Yamanaka A, Yato K, Yoshii K, Watashi K, Aizaki H, et al. High-throughput 596 neutralization assay for multiple flaviviruses based on single-round infectious particles using dengue 597 virus type 1 reporter replicon. Sci Rep. 2018;8(1):16624. 598 35. Litzba N, Zelena H, Kreil TR, Niklasson B, Kuhlmann-Rabens I, Remoli ME, et al. Evaluation of 599 different serological diagnostic methods for tick-borne encephalitis virus: enzyme-linked 600 immunosorbent, immunofluorescence, and neutralization assay. Vector Borne Zoonotic Dis. 601 2014;14(2):149-59. 602 36. Reusken C, Boonstra M, Rugebregt S, Scherbeijn S, Chandler F, Avsic-Zupanc T, et al. An 603 evaluation of serological methods to diagnose tick-borne encephalitis from serum and cerebrospinal 604 fluid. J Clin Virol. 2019;120:78-83. 605 37. Dobler G. Diagnosis. The TBE book. 6th edition ed: Global Health Press; 2023. 606 38. Bestehorn-Willmann M, Girl P, Greiner F, Mackenstedt U, Dobler G, Lang D. Increased 607 Vaccination Diversity Leads to Higher and Less-Variable Neutralization of TBE Viruses of the European 608 Subtype. Vaccines (Basel). 2023;11(6). 609 39. Geisslreiter B, Kluger G, Eschermann K, Kiwull L, Staudt M, Dobler G, et al. High neutralizing 610 antibody mismatch as a possible reason for vaccine failure in two children with severe tick-borne 611 encephalitis. Ticks Tick Borne Dis. 2023;14(4):102158.

- 612 40. Control CfD. Yellow Fever Vaccine 2021 [Available from:
- 613 <u>https://www.cdc.gov/yellowfever/vaccine/index.html</u>.
- 614 41. Baryshnikova V, Turchenko Y, Tuchynskaya K, Belyaletdinova I, Butenko A, Dereventsova A, et
- al. Recombinant TBEV Protein E of the Siberian Subtype Is a Candidate Antigen in the ELISA Test
- 616 System for Differential Diagnosis. Diagnostics (Basel). 2023;13(20).
- 617 42. Pierson TC, Diamond MS. The continued threat of emerging flaviviruses. Nat Microbiol.
- 618 2020;5(6):796-812.

619